147 related articles for article (PubMed ID: 37751862)
1. Mechanisms of Secondary Leukemia Development Caused by Treatment with DNA Topoisomerase Inhibitors.
Lomov NA; Viushkov VS; Rubtsov MA
Biochemistry (Mosc); 2023 Jul; 88(7):892-911. PubMed ID: 37751862
[TBL] [Abstract][Full Text] [Related]
2. Recurrent Translocations in Topoisomerase Inhibitor-Related Leukemia Are Determined by the Features of DNA Breaks Rather Than by the Proximity of the Translocating Genes.
Lomov NA; Viushkov VS; Ulianov SV; Gavrilov AA; Alexeyevsky DA; Artemov AV; Razin SV; Rubtsov MA
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077220
[TBL] [Abstract][Full Text] [Related]
3. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors.
Aplan PD; Chervinsky DS; Stanulla M; Burhans WC
Blood; 1996 Apr; 87(7):2649-58. PubMed ID: 8639880
[TBL] [Abstract][Full Text] [Related]
4. Secondary leukemias induced by topoisomerase-targeted drugs.
Felix CA
Biochim Biophys Acta; 1998 Oct; 1400(1-3):233-55. PubMed ID: 9748598
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II and the etiology of chromosomal translocations.
Felix CA; Kolaris CP; Osheroff N
DNA Repair (Amst); 2006 Sep; 5(9-10):1093-108. PubMed ID: 16857431
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents.
Cowell IG; Austin CA
Int J Environ Res Public Health; 2012 Jun; 9(6):2075-91. PubMed ID: 22829791
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11).
Domer PH; Head DR; Renganathan N; Raimondi SC; Yang E; Atlas M
Leukemia; 1995 Aug; 9(8):1305-12. PubMed ID: 7643617
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus.
Stanulla M; Wang J; Chervinsky DS; Aplan PD
Leukemia; 1997 Apr; 11(4):490-6. PubMed ID: 9096688
[TBL] [Abstract][Full Text] [Related]
9. Leukemias related to treatment with DNA topoisomerase II inhibitors.
Felix CA
Med Pediatr Oncol; 2001 May; 36(5):525-35. PubMed ID: 11340607
[TBL] [Abstract][Full Text] [Related]
10. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders.
Rowley JD; Reshmi S; Sobulo O; Musvee T; Anastasi J; Raimondi S; Schneider NR; Barredo JC; Cantu ES; Schlegelberger B; Behm F; Doggett NA; Borrow J; Zeleznik-Le N
Blood; 1997 Jul; 90(2):535-41. PubMed ID: 9226152
[TBL] [Abstract][Full Text] [Related]
11. Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity.
Cowell IG; Sondka Z; Smith K; Lee KC; Manville CM; Sidorczuk-Lesthuruge M; Rance HA; Padget K; Jackson GH; Adachi N; Austin CA
Proc Natl Acad Sci U S A; 2012 Jun; 109(23):8989-94. PubMed ID: 22615413
[TBL] [Abstract][Full Text] [Related]
12. Chlorpyrifos Induces MLL Translocations Through Caspase 3-Dependent Genomic Instability and Topoisomerase II Inhibition in Human Fetal Liver Hematopoietic Stem Cells.
Lu C; Liu X; Liu C; Wang J; Li C; Liu Q; Li Y; Li S; Sun S; Yan J; Shao J
Toxicol Sci; 2015 Oct; 147(2):588-606. PubMed ID: 26198043
[TBL] [Abstract][Full Text] [Related]
13. Chromatin structural elements and chromosomal translocations in leukemia.
Zhang Y; Rowley JD
DNA Repair (Amst); 2006 Sep; 5(9-10):1282-97. PubMed ID: 16893685
[TBL] [Abstract][Full Text] [Related]
14. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.
Megonigal MD; Cheung NK; Rappaport EF; Nowell PC; Wilson RB; Jones DH; Addya K; Leonard DG; Kushner BH; Williams TM; Lange BJ; Felix CA
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2814-9. PubMed ID: 10706619
[TBL] [Abstract][Full Text] [Related]
15. Bioflavonoids cause DNA double-strand breaks and chromosomal translocations through topoisomerase II-dependent and -independent mechanisms.
Goodenow D; Emmanuel F; Berman C; Sahyouni M; Richardson C
Mutat Res Genet Toxicol Environ Mutagen; 2020 Jan; 849():503144. PubMed ID: 32087851
[TBL] [Abstract][Full Text] [Related]
16. Bioflavonoids promote stable translocations between MLL-AF9 breakpoint cluster regions independent of normal chromosomal context: Model system to screen environmental risks.
Bariar B; Vestal CG; Deem B; Goodenow D; Ughetta M; Engledove RW; Sahyouni M; Richardson C
Environ Mol Mutagen; 2019 Mar; 60(2):154-167. PubMed ID: 30387535
[TBL] [Abstract][Full Text] [Related]
17. Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions.
Sung PA; Libura J; Richardson C
DNA Repair (Amst); 2006 Sep; 5(9-10):1109-18. PubMed ID: 16809075
[TBL] [Abstract][Full Text] [Related]
18. Dietary flavonoids induce MLL translocations in primary human CD34+ cells.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Janssen J; Maas LM; Godschalk RW; Nijhuis JG; van Schooten FJ
Carcinogenesis; 2007 Aug; 28(8):1703-9. PubMed ID: 17468513
[TBL] [Abstract][Full Text] [Related]
19. TDP2 suppresses chromosomal translocations induced by DNA topoisomerase II during gene transcription.
Gómez-Herreros F; Zagnoli-Vieira G; Ntai I; Martínez-Macías MI; Anderson RM; Herrero-Ruíz A; Caldecott KW
Nat Commun; 2017 Aug; 8(1):233. PubMed ID: 28794467
[TBL] [Abstract][Full Text] [Related]
20. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children.
Felix CA; Hosler MR; Winick NJ; Masterson M; Wilson AE; Lange BJ
Blood; 1995 Jun; 85(11):3250-6. PubMed ID: 7756657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
